KALA BIO, Inc. (KALA) stock

KALANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 6/30

$0.14−0.02 (-13.79%)

Close on Nov 13, 2026Market cap $2.68MP/E –Yield –

Kala Bio gross margin

Gross margin is gross profit as a percentage of revenue.

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q1 FY2019	Mar 31, 2019	82.6%	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is KALA.

Advertisement
300 × 250

See a number that looks wrong?